Aug. 13 at 10:18 AM
Citizens⬇️
$SPRB's PT to
$144 from
$150, reiterated Market Outperform and said:
∘ Pipeline update – SPRB remains on track to submit its BLA for TA-ERT BLA in 4Q26, where we think Priority Review is likely given the high unmet need in MPS IIIB and absence of approved therapies.
SPRB expects to start the Transform confirmatory study in 4Q26, a randomized controlled study expected to enroll ~14 severe MPS IIIB patients and will evaluate cognition as the primary endpoint.
Additionally, the TA-ERT EAP will start next quarter, which is expected to enroll ~10 U.S. patients who are not eligible for the confirmatory study, providing access to therapy while supporting continued experience with TA-ERT ahead of its potential approval.
Here's what Citizens went on to say: https://x.com/Quantumup1/status/2087845923489542207?s=20
